Rania Makboul

Rania Makboul


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2014 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MMMohamed Makboul
Mohamed Makboul
RMRania Makboul
Rania Makboul
AAAssem Hk Abdelhafez
Assem Hk Abdelhafez
SHSafaa Said Hassan
Safaa Said Hassan
SYSherif M Youssif
Sherif M Youssif

26 January 2018 in Egyptian Journal of Forensic Sciences
Verified
Journal Article
Open access
PDF file
WMWafaa M. Abdel Moneim
Wafaa M. Abdel Moneim
HYHeba Yassa
Heba Yassa
RMRania Makboul
Rania Makboul
NMNada A. Mohamed
Nada A. Mohamed
Monosodium Glutamate is a silent toxin in our food, especially our kids’ food. Some of the products in the market contain MSG in a level exceed the European limit. Sixty male albino rats divided into three groups, control group, and treated groups, the first with a low dose of MSG (1/20 LD50) and the second with a high dose of MSG (1/10 LD50). All animals examined for cognitive function, serotonin level. The second part in this study, examination of some commercial food for the presence of MSG and its level by HPLC. MSG affected the cognitive function of treated rats in small and high doses of MSG. The weight of the animals in treated group with a high dose of MSG was significantly increased in comparison with the control group. Also, the cognitive function of the rats administered MSG affected significantly either in low dose and in high dose. Some of the studied commercial food in the market like Kapsa and Indomi contains a higher level of MSG more than the European limit. MSG has many dangerous effects on health especially kids, so it is so necessary to declare its presence or absence and level on the labels of the products.

1 January 2015 in Korean Journal of Urology
Verified
Journal Article
Open access
RMRania Makboul
Rania Makboul
ARAbeer El-Refaiy M. Refaiy
Abeer El-Refaiy M. Refaiy
FBFatma Ahmed Mahmoud Badary
Fatma Ahmed Mahmoud Badary
IAIslam F. Abdelkawi
Islam F. Abdelkawi
AMAxel S. Merseburger
Axel S. Merseburger
RMRabab Ahmed Ahmed Mohammed
Rabab Ahmed Ahmed Mohammed
To compare the expression of survivin and its association with clinicopathological criteria in major types of urinary bladder carcinoma, specifically, transitional cell carcinoma with and without squamous differentiation and squamous cell carcinoma. Immunohistochemical staining for survivin and Ki67 was performed on paraffin-embedded sections of 104 carcinomas: 52 transitional cell carcinoma, 20 transitional cell carcinoma with squamous differentiation, and 32 squamous cell carcinoma. Expression of survivin in >10% of tumor cells was described as altered survivin status. Ki67 staining in >20% of tumor cells was described as a high proliferation index. Altered survivin expression was detected in 60/104 specimens (58%) and was significantly more frequent in transitional cell carcinoma (78%) than in squamous cell carcinoma (38%) or transitional cell carcinoma with squamous differentiation (40%) (p<0.0001). In transitional cell carcinoma but not in squamous cell carcinoma, altered survivin status was associated with higher tumor grade, higher proliferation index, and recurrence. In the whole specimens, altered survivin expression was significantly associated with advanced stage (p<0.001), recurrence (p=0.005), distant metastasis (p<0.001), and death (p=0.001). In the multivariate analysis, altered survivin was an independent poor prognostic factor for recurrence. Unlike in transitional cell carcinoma, alteration of survivin expression in squamous cell carcinoma occurs less frequently and is not associated with features of tumor aggression or patient outcome. These findings raise a question: are urinary bladder carcinoma patients with squamous cell carcinoma type suitable candidates for survivin vaccine? This is an important question to be answered before approving the vaccine in management.

1 August 2021 in Applied Physiology, Nutrition, and Metabolism
Verified
Journal Article
Closed access
OAOmyma G. Ahmed
Omyma G. Ahmed
Ghaydaa ShehataGhaydaa Shehata
Ghaydaa Shehata
RARasha Mohammed Ali
Rasha Mohammed Ali
RMRania Makboul
Rania Makboul
Elsayed Fathi Abd_AllahElsayed Fathi Abd_Allah
Elsayed Fathi Abd_Allah
NMNessren Mahmoud
Nessren Mahmoud
The current study investigated the role of epigenetic dysregulation of brain derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP) genes and oxidative stress as possible mechanisms of autistic-like behaviors in neonatal isolation model in rats and the impact of folic acid administration on these parameters. Forty Wistar albino pups were used as follows: control, folic acid administered, isolated, and isolated folic acid treated groups. Isolated pups were separated from their mothers for 90 min daily from postnatal day (PND) 1 to 11. Pups (isolated or control) received either the vehicle or folic acid (4 mg/kg/day) orally from PND 1 to 29. Behavioral tests were done from PND 30 to 35. Oxidative stress markers and antioxidant defense in the frontal cortex homogenate were determined. DNA methylation of BDNF and GFAP genes was determined by qPCR. Histopathological examination was carried out. Neonatal isolation produced autistic-like behaviors that were associated with BDNF and GFAP hypomethylation, increased oxidative stress, increased inflammatory cell infiltration, and structural changes in the frontal cortex. Folic acid administration concurrently with isolation reduced neonatal isolation-induced autistic-like behaviors, decreased oxidative stress, regained BDNF and GFAP gene methylation, and ameliorated structural changes in the frontal cortices of isolated folic acid treated rats. Novelty: Neonatal isolation induces “autistic-like” behavior and these behaviors are reversed by folic acid supplementation. Neonatal isolation induces DNA hypomethylation of BDNF and GFAP, increased oxidative stress markers, and neuroinflammation. All of these changes were reversed by daily folic acid supplementation.

1 June 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
RMRania Makboul
Rania Makboul
HHHesham M. Hassan
Hesham M. Hassan
ARAbeer Refaiy
Abeer Refaiy
IAIslam F. Abdelkawi
Islam F. Abdelkawi
ASAhmed Abdelhamid Shahat
Ahmed Abdelhamid Shahat
RMRabab Ahmed Ahmed Mohammed
Rabab Ahmed Ahmed Mohammed

1 January 2017 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
Rabab MohammedRabab Mohammed
Rabab Mohammed
RMRania Makboul
Rania Makboul
DEDalia A.H. Elsers
Dalia A.H. Elsers
TETarek M.A.M. Ph.D. Elsaba
Tarek M.A.M. Ph.D. Elsaba
ATAbeer M.A.B. Thalab
Abeer M.A.B. Thalab
OSOmar M. Shaaban
Omar M. Shaaban
Amplification of HER-2 gene and overexpression of HER-2 receptor play a significant role in the progression of a number of malignancies such as breast cancer. Trastuzumab (anti-HER-2 therapeutic agent) has been used successfully in treatment of breast cancer. The aim of this study was to assess the pattern of HER-2 gene amplification and of HER-2 receptor expression in a spectrum of serous and mucinous ovarian tumors to determine whether HER-2 is altered in these neoplasms similar to that occurring in breast cancer. Formalin-fixed paraffin-embedded microarray tissue sections from 212 specimens were stained with HER-2 antibody using immunohistochemistry and with anti-HER-2 DNA probe using chromogenic in situ hybridization. Specimens consisted of 65 benign tumors (50 serous and 15 mucinous), 26 borderline (13 serous and 13 mucinous), 73 malignant tumors (53 serous carcinoma and 20 mucinous carcinoma), 18 metastatic deposits (13 serous and 5 mucinous), in addition to 30 normal tissues (16 ovarian surface and 14 normal fallopian tube). HER-2 protein–positive expression was not detected in the normal or the benign tissues. Borderline neoplasms showed positive staining, but no overexpression. HER-2 overexpression was seen only in 4 carcinoma specimens: 1/53 (1.8%) primary serous carcinomas and 3/20 (15%) primary mucinous carcinomas. HER-2 gene amplification was seen in 4 specimens: 2 primary mucinous carcinomas and 2 malignant deposits of these 2 mucinous carcinomas. In conclusion, alteration of HER-2 was not detected in ovarian serous neoplasms; however, in mucinous carcinoma, HER-2 amplification and overexpression occur.